International Journal of Molecular Sciences (Aug 2024)

Dietary Polyphenols and Gut Microbiota Cross-Talk: Molecular and Therapeutic Perspectives for Cardiometabolic Disease: A Narrative Review

  • Raquel Cano,
  • Valmore Bermúdez,
  • Nestor Galban,
  • Bermary Garrido,
  • Raquel Santeliz,
  • Maria Paula Gotera,
  • Pablo Duran,
  • Arturo Boscan,
  • Ana-Karina Carbonell-Zabaleta,
  • Samuel Durán-Agüero,
  • Diana Rojas-Gómez,
  • Jorge González-Casanova,
  • Waldo Díaz-Vásquez,
  • Maricarmen Chacín,
  • Lissé Angarita Dávila

DOI
https://doi.org/10.3390/ijms25169118
Journal volume & issue
Vol. 25, no. 16
p. 9118

Abstract

Read online

The intricate interplay between the gut microbiota and polyphenols has emerged as a captivating frontier in understanding and potentially harnessing the therapeutic potential of these bioactive compounds. Phenolic compounds, renowned for their antioxidant, anti-inflammatory, antidiabetic, and anticancer properties, are subject to intricate transformations within the gut milieu, where the diverse microbial ecosystem exerts profound effects on their metabolism and bioavailability. Conversely, polyphenols exhibit a remarkable capacity to modulate the composition and activity of the gut microbiota, fostering a bidirectional relationship that extends beyond mere nutrient processing. This symbiotic interaction holds significant implications for human health, particularly in cardiometabolic diseases such as diabetes mellitus, metabolic-dysfunction-associated steatotic liver disease, and cardiovascular disease. Through a comprehensive exploration of molecular interactions, this narrative review elucidates the reciprocal dynamics between the gut microbiota and polyphenols, unveiling novel avenues for therapeutic intervention in cardiometabolic disorders. By unravelling the intricate cross-talk between these two entities, this review underscores the multifaceted roles of polyphenols in overall health and the pivotal role of gut microbiota modulation as a promising therapeutic strategy in mitigating the burden of cardiometabolic diseases.

Keywords